953 related articles for article (PubMed ID: 31526274)
1. Complex interactions between the microbiome and cancer immune therapy.
Schwartz DJ; Rebeck ON; Dantas G
Crit Rev Clin Lab Sci; 2019 Dec; 56(8):567-585. PubMed ID: 31526274
[TBL] [Abstract][Full Text] [Related]
2. Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer.
Hayase E; Jenq RR
Genome Med; 2021 Jun; 13(1):107. PubMed ID: 34162429
[TBL] [Abstract][Full Text] [Related]
3. Modulating the gut microbiota by probiotics, prebiotics, postbiotics, and fecal microbiota transplantation: An emerging trend in cancer patient care.
Ciernikova S; Sevcikova A; Drgona L; Mego M
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):188990. PubMed ID: 37742728
[TBL] [Abstract][Full Text] [Related]
4. Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers.
McQuade JL; Ologun GO; Arora R; Wargo JA
Curr Oncol Rep; 2020 Jun; 22(7):74. PubMed ID: 32577835
[TBL] [Abstract][Full Text] [Related]
5. Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite.
Renga G; Nunzi E; Pariano M; Puccetti M; Bellet MM; Pieraccini G; D'Onofrio F; Santarelli I; Stincardini C; Aversa F; Riuzzi F; Antognelli C; Gargaro M; Bereshchenko O; Ricci M; Giovagnoli S; Romani L; Costantini C
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35236743
[TBL] [Abstract][Full Text] [Related]
6. The Challenge of ICIs Resistance in Solid Tumours: Could Microbiota and Its Diversity Be Our Secret Weapon?
Roberto M; Carconi C; Cerreti M; Schipilliti FM; Botticelli A; Mazzuca F; Marchetti P
Front Immunol; 2021; 12():704942. PubMed ID: 34489956
[TBL] [Abstract][Full Text] [Related]
7. Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.
Wu J; Wang S; Zheng B; Qiu X; Wang H; Chen L
Front Immunol; 2021; 12():669150. PubMed ID: 34267748
[TBL] [Abstract][Full Text] [Related]
8. The impact of modulating the gastrointestinal microbiota in cancer patients.
Morkūnas E; Skiecevičienė J; Kupčinskas J
Best Pract Res Clin Gastroenterol; 2020; 48-49():101700. PubMed ID: 33317795
[TBL] [Abstract][Full Text] [Related]
9. Microbiome bacterial influencers of host immunity and response to immunotherapy.
Yousefi Y; Baines KJ; Maleki Vareki S
Cell Rep Med; 2024 Apr; 5(4):101487. PubMed ID: 38547865
[TBL] [Abstract][Full Text] [Related]
10. Gut Microbiota in Cancer Immune Response and Immunotherapy.
Zhou CB; Zhou YL; Fang JY
Trends Cancer; 2021 Jul; 7(7):647-660. PubMed ID: 33674230
[TBL] [Abstract][Full Text] [Related]
11. Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.
Borgers JSW; Burgers FH; Terveer EM; van Leerdam ME; Korse CM; Kessels R; Flohil CC; Blank CU; Schumacher TN; van Dijk M; Henderickx JGE; Keller JJ; Verspaget HW; Kuijper EJ; Haanen JBAG
BMC Cancer; 2022 Dec; 22(1):1366. PubMed ID: 36585700
[TBL] [Abstract][Full Text] [Related]
12. Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis.
Halsey TM; Thomas AS; Hayase T; Ma W; Abu-Sbeih H; Sun B; Parra ER; Jiang ZD; DuPont HL; Sanchez C; El-Himri R; Brown A; Flores I; McDaniel L; Ortega Turrubiates M; Hensel M; Pham D; Watowich SS; Hayase E; Chang CC; Jenq RR; Wang Y
Sci Transl Med; 2023 Jun; 15(700):eabq4006. PubMed ID: 37315113
[TBL] [Abstract][Full Text] [Related]
13. Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition.
Guardamagna M; Berciano-Guerrero MA; Villaescusa-González B; Perez-Ruiz E; Oliver J; Lavado-Valenzuela R; Rueda-Dominguez A; Barragán I; Queipo-Ortuño MI
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233289
[TBL] [Abstract][Full Text] [Related]
14. Targeted modulation of gut and intra-tumor microbiota to improve the quality of immune checkpoint inhibitor responses.
Wang W; Fan J; Zhang C; Huang Y; Chen Y; Fu S; Wu J
Microbiol Res; 2024 May; 282():127668. PubMed ID: 38430889
[TBL] [Abstract][Full Text] [Related]
15. The Gastrointestinal Microbiome and Immune Checkpoint Inhibitors: A Review of Human Interventional Studies Among Melanoma Patients.
Natarelli N; Aflatooni S; Boby A; Krenitsky A; Grichnik J
J Drugs Dermatol; 2024 Feb; 23(2):78-84. PubMed ID: 38306142
[TBL] [Abstract][Full Text] [Related]
16. Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes.
Ting NL; Lau HC; Yu J
Gut; 2022 Jul; 71(7):1412-1425. PubMed ID: 35277453
[TBL] [Abstract][Full Text] [Related]
17. Gut microbiome in modulating immune checkpoint inhibitors.
Li X; Zhang S; Guo G; Han J; Yu J
EBioMedicine; 2022 Aug; 82():104163. PubMed ID: 35841869
[TBL] [Abstract][Full Text] [Related]
18. Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology.
Jamal R; Messaoudene M; de Figuieredo M; Routy B
Semin Immunol; 2023 May; 67():101754. PubMed ID: 37003055
[TBL] [Abstract][Full Text] [Related]
19. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
[TBL] [Abstract][Full Text] [Related]
20. Impact of the gut microbiome on immune checkpoint inhibitor efficacy-a systematic review.
Pierrard J; Seront E
Curr Oncol; 2019 Dec; 26(6):395-403. PubMed ID: 31896938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]